T1	Participants 147 222	176 eligible patients with advanced suboptimally operated ovarian carcinoma
T2	Participants 924 989	Thirty-seven platinum-resistant and 27 platinum-sensitive tumours
T3	Participants 1256 1296	Patients with platinum-sensitive tumours
